Projected life expectancy of people with HIV according to timing of diagnosis

Background and objectives:Effective antiretroviral therapy (ART) has contributed greatly toward survival for people with HIV, yet many remain undiagnosed until very late. Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy. Methods:A stochastic computer simulation model of HIV infection and the effect of ART was used to estimate life expectancy and determine the distribution of potential lifetime outcomes of an MSM, aged 30 years, who becomes HIV positive in 2010. The effect of altering the diagnosis rate was investigated. Results:Assuming a high rate of HIV diagnosis (median CD4 cell count at diagnosis, 432 cells/&mgr;l), projected median age at death (life expectancy) was 75.0 years. This implies 7.0 years of life were lost on average due to HIV. Cumulative risks of death by 5 and 10 years after infection were 2.3 and 5.2%, respectively. The 95% uncertainty bound for life expectancy was (68.0,77.3) years. When a low diagnosis rate was assumed (diagnosis only when symptomatic, median CD4 cell count 140 cells/&mgr;l), life expectancy was 71.5 years, implying an average 10.5 years of life lost due to HIV. Conclusion:If low rates of virologic failure observed in treated patients continue, predicted life expectancy is relatively high in people with HIV who can access a wide range of antiretrovirals. The greatest risk of excess mortality is due to delays in HIV diagnosis.

[1]  J Elford,et al.  More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. , 1991, Journal of acquired immune deficiency syndromes.

[2]  L. Kuller,et al.  Cigarette smoking and mortality , 1991 .

[3]  C. Sabin,et al.  Immunodeficiency and the risk of death in HIV infection. , 1992, JAMA.

[4]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[5]  J. Nielsen,et al.  Survival differences in European patients with AIDS, 1979–89 , 1994, BMJ.

[6]  J J Goedert,et al.  Natural history of HIV-1 cell-free viremia. , 1995, JAMA.

[7]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[8]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[9]  A. Hatzakis,et al.  Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  J J Goedert,et al.  Longitudinal HIV-1 RNA levels in a cohort of homosexual men. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[11]  J. Goedert,et al.  Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia , 1998, AIDS.

[12]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[13]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[14]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[15]  C. Sabin,et al.  Virological response to protease inhibitor therapy in an HIV clinic cohort. , 1999, AIDS.

[16]  R. Manfredi,et al.  Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[18]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[19]  A. Phillips,et al.  Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens , 2000, AIDS.

[20]  C. Rouzioux,et al.  Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection , 2000, AIDS.

[21]  C. Sabin,et al.  Course of Viral Load Throughout HIV‐1 Infection , 2000, Journal of acquired immune deficiency syndromes.

[22]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.

[23]  C. Sabin,et al.  Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre , 2001, AIDS.

[24]  S. Danner,et al.  Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response , 2000, Antiviral therapy.

[25]  K. Juel,et al.  Abstention from smoking extends life and compresses morbidity: a population based study of health expectancy among smokers and never smokers in Denmark , 2001, Tobacco control.

[26]  M. Johnson,et al.  Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations , 2001, Journal of medical virology.

[27]  R Weber,et al.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.

[28]  A. Sönnerborg,et al.  Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy , 2001, AIDS.

[29]  Jacques Izopet,et al.  Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.

[30]  J. Goedert,et al.  Association of cancer with AIDS-related immunosuppression in adults. , 2001, JAMA.

[31]  Sundhiya Mandalia,et al.  Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome , 2002, AIDS.

[32]  P. Tebas,et al.  Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. , 2002, The Journal of infectious diseases.

[33]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[34]  B. Schmidt,et al.  No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. , 2002, Journal of acquired immune deficiency syndromes.

[35]  A. Trkola,et al.  HIV RNA in plasma rebounds within days during structured treatment interruptions , 2003, AIDS.

[36]  J. Gallant,et al.  Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Mark S Roberts,et al.  Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[38]  D. Costagliola,et al.  Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Terri Wrin,et al.  Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response , 2003, AIDS.

[40]  A. Mocroft,et al.  Virological rebound after suppression on highly active antiretroviral therapy , 2003, AIDS.

[41]  J. Moatti,et al.  Impact of Early versus Late Adherence to Highly Active Antiretroviral Therapy on Immuno-Virological Response: A 3-Year Follow-Up Study , 2002, Antiviral therapy.

[42]  Gary Collins,et al.  Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.

[43]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[44]  D. Bangsberg,et al.  Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. , 2004, The Journal of antimicrobial chemotherapy.

[45]  Bruno Ledergerber,et al.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.

[46]  D. Bangsberg,et al.  Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. , 2004, The Journal of infectious diseases.

[47]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[48]  C. Tinelli,et al.  CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy , 2004, AIDS.

[49]  D. Skiest,et al.  It Is Safe to Stop Antiretroviral Therapy in Patients With Preantiretroviral CD4 Cell Counts >250 cells/μL , 2004, Journal of acquired immune deficiency syndromes.

[50]  A. Phillips,et al.  Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.

[51]  N. Pantazis,et al.  Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates , 2004, AIDS.

[52]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[53]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[54]  M. Knoll,et al.  Extended antiretroviral treatment interruption in HIV‐infected patients with long‐term suppression of plasma HIV RNA , 2005, HIV medicine.

[55]  M. Moroni,et al.  Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice: Results From the Italian Cohort of Antiretroviral-Naive Patients , 2005, Journal of acquired immune deficiency syndromes.

[56]  F. Wit,et al.  Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study , 2005, AIDS.

[57]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[58]  Nikos Pantazis,et al.  Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop‐outs , 2005 .

[59]  Mark S Roberts,et al.  Estimating the proportion of patients infected with HIV who will die of comorbid diseases. , 2005, The American journal of medicine.

[60]  B. Gazzard,et al.  The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. , 2005, The Journal of infectious diseases.

[61]  B. Gazzard,et al.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.

[62]  J. Margolick,et al.  Interruption and Discontinuation of Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study , 2005, Journal of acquired immune deficiency syndromes.

[63]  H. Fleury,et al.  Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 106 cells/l , 2005, AIDS.

[64]  Milton C Weinstein,et al.  Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.

[65]  M. Lederman,et al.  Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.

[66]  A. Mocroft,et al.  Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. , 2005, AIDS research and human retroviruses.

[67]  Jonathan A C Sterne,et al.  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.

[68]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[69]  J. Gatell,et al.  Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. , 2006, Archives of internal medicine.

[70]  J. Stockman Expanded Screening for HIV in the United States—an Analysis of Cost-effectiveness , 2006 .

[71]  A. Mocroft,et al.  Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe , 2006, Journal of acquired immune deficiency syndromes.

[72]  C. Sabin,et al.  The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004) , 2006, AIDS.

[73]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[74]  C. Sabin,et al.  Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. , 2007, Archives of internal medicine.

[75]  Ewout W Steyerberg,et al.  Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. , 2007, Archives of internal medicine.

[76]  B. Gazzard,et al.  Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study , 2007, The Lancet.

[77]  Gitte Pedersen,et al.  Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.

[78]  J. Lundgren,et al.  HIV in the UK 1980–2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy , 2007, HIV medicine.

[79]  S. Twu,et al.  Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. , 2006, QJM : monthly journal of the Association of Physicians.

[80]  C. Latkin,et al.  Correlates of Lending Needles/Syringes Among HIV-Seropositive Injection Drug Users , 2007, Journal of acquired immune deficiency syndromes.

[81]  A. Phillips,et al.  Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. , 2007, The Journal of infectious diseases.

[82]  C. Katlama,et al.  HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.

[83]  C. Sabin,et al.  Stability of antiretroviral regimens in patients with viral suppression , 2008, AIDS.

[84]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[85]  F. Raffi,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults , 2008, HIV medicine.

[86]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[87]  D. Pillay,et al.  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? , 2008, The Journal of antimicrobial chemotherapy.

[88]  A. Phillips,et al.  The role of HIV in serious diseases other than AIDS , 2008, AIDS.

[89]  B. Gazzard British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[90]  John T Brooks,et al.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[91]  R. Weber,et al.  Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[92]  E. Ricci,et al.  Cardiovascular risk assessment in antiretroviral-naïve HIV patients. , 2009, AIDS patient care and STDs.

[93]  B. Yip,et al.  The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time , 2009, Journal of acquired immune deficiency syndromes.

[94]  D. Francisci,et al.  HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction , 2009, AIDS (London).

[95]  A. Phillips,et al.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.

[96]  A. Phillips,et al.  Long-term trends in adherence to antiretroviral therapy from start of HAART , 2010, AIDS.

[97]  M. Fisher Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study , 2010, The Lancet.

[98]  Coris,et al.  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study , 2010 .

[99]  Peter Reiss,et al.  Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals , 2010, AIDS.

[100]  C. Leen,et al.  Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations * , 2010, HIV medicine.

[101]  A. Mocroft,et al.  Chronic Kidney Disease and Exposure to ART in a large cohort with Long-term Follow-up: The EuroSIDA study , 2010 .

[102]  P. Volberding,et al.  Antiretroviral therapy and management of HIV infection , 2010, The Lancet.

[103]  Xinjiang Zhang,et al.  Life Expectancy After HIV Diagnosis Based on National HIV Surveillance Data From 25 States, United States , 2010, Journal of acquired immune deficiency syndromes.

[104]  Delpech,et al.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  P. Harrigan,et al.  Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.